Welcome to X Pharma Plus

X Pharma Plus ensures that all your dossier authoring needs meet global regulatory standards for quality, safety, and efficacy. We provide expert regulatory support for the registration of human medicinal products—from oral solids and parenteral to the most complex therapies. With deep expertise across all therapeutic categories, we deliver a right-first-time quality approach to accelerate approvals and bring your products to market faster.

Dossier Authoring Services– Overview

A robust Common Technical Document (CTD) dossier provides Health Authorities (HAs) with complete technical and scientific information necessary to evaluate the quality, safety, and efficacy of human medicinal products. X Pharma Plus leverages its dossier authoring expertise to support product registration by delivering comprehensive, HA-compliant documentation and strategic recommendations to meet regulatory requirements.

From initial product registration to global market expansion, our experts ensure all regulatory expectations are met to avoid HA rejections. We facilitate successful, on-time approvals by providing complete support during HA reviews and maintaining compliance throughout the product lifecycle. By authoring high-quality dossiers that adhere to global regulatory standards, X Pharma Plus enables manufacturers and sponsors to achieve timely approvals and expedited market entry.

Dossier Authoring Services

“End-to-end preparation and compilation of regulatory documents in CTD/eCTD formats for global submissions.”

  • Authoring, gap analysis, and submission of complete dossiers for regulatory applications with a right-first-time approach
  • Preparation of CTD dossiers and country-specific dossiers to ensure no administrative rejections from Health Authorities (HAs)
  • Deep knowledge of HA-specific requirements to support market entry in multiple regions
  • Guidance on mitigating gaps during the review of supporting documents and data
  • Expertise in registering all dosage forms, therapeutic categories, and product types including
  • Innovator drugs, biologics, biosimilars, generic drugs
  • Drug-drug combinations, drug-device combination products, OTC drugs
  • APIs, excipients, and packaging materials
  • Drafting of HA correspondence and handling deficiency responses
  • Handling all types of applications: NDAs, BLAs, NDSs, MAAs, ANDAs, ANDSs, DMFs, ASMFs, CEPs, and country-specific dossiers
  • Ex-FDA/EMA experts providing regulatory strategy guidance and support for HA query responses
  • Defining regulatory submission pathways and strategic advice for smooth approvals
  • Comprehensive regulatory roadmap for dossier submission procedures
  • Thorough assessment of supporting documents against country-specific requirements
  • Specialized expertise in complex products, biologics, biosimilars, vaccines, NDAs, ANDAs, hybrid applications, drug-device combinations, APIs, excipients, and packaging materials
  • Guidance on expedited review programs, CGTs, and other regulatory pathways
  • Proactive gap identification to prevent rejections, save time, and reduce application fees
  • Standardized templates, workflows, and automation to save time and effort
  • Continuous compliance monitoring to prevent potential findings

Common Technical Document (CTD) Services

Streamlined, comprehensive CTD templates designed to meet global regulatory standards and ensure submission excellence.

  • We structure, compile, and review all CTD modules to meet ICH guidelines and country-specific requirements for smooth global submissions.
  • Our expertise ensures accuracy, consistency, and regulatory compliance, reducing review cycles and accelerating approvals.

Biologics Registration Services

Expert support for the seamless registration of biologics across multiple international markets, simplifying complex regulatory pathways.

  • We manage end-to-end registration of biologics, ensuring compliance with global regulatory frameworks and authority expectations.
  • Our expertise streamlines submission preparation and interactions with regulators, enabling faster approvals for innovative biologic therapies.

Subscribe for Updates